Company: INDP
Filing Date: 2025-03-13
Form Type: 10-K
Source: 0001493152-25-010136
Chunk: 1371

Company: Indaptus Therapeutics, Inc.
Filing Date: 2025-03-13
Form: 10-K
Item: Item 1A
Chunk 1371
---
 commercializing the infringing
technology or product. In addition, in any such proceeding or litigation, we could be found liable for monetary damages, including treble
damages and attorneys’ fees, if we are found to have willfully infringed a patent. A finding of infringement could prevent us from
commercializing our product candidates or force us to cease some of our business operations, which could materially and adversely affect
our business, financial condition and results of operations. Any claims by third parties that we have misappropriated their confidential
information or trade secrets could have a similar material and adverse effect on our business, financial condition and results of operations.
In addition, any uncertainties resulting from the initiation and continuation of any litigation could have a material adverse effect
on our ability to raise the funds necessary to continue our operations.

Any
claims or lawsuits relating to infringement of intellectual property rights brought by or against us will be costly and time consuming
and may adversely affect our business, financial condition and results of operations.

We
may be required to initiate litigation to enforce or defend our licensed and owned intellectual property. Lawsuits to protect our intellectual
property rights can be very time consuming and costly. There is a substantial amount of litigation involving patent and other intellectual
property rights in the biopharmaceutical industry generally. Such litigation or proceedings could substantially increase our operating
expenses and reduce the resources available for development activities or any future sales, marketing or distribution activities.

In
any infringement litigation, any award of monetary damages we receive may not be commercially valuable. Furthermore, because of the substantial
amount of discovery required in connection with intellectual property litigation, there is a risk that some of our confidential information
could be compromised by disclosure during litigation. Moreover, there can be no assurance that we will have sufficient financial or other
resources to file and pursue such infringement claims, which typically last for years before they are resolved. Further, any claims we
assert against a perceived infringer could provoke these parties to assert counterclaims against us alleging that we have infringed their
patents. Some of our competitors may be able to sustain the costs of such litigation or proceedings more effectively than we can because
of their greater financial resources. Uncertainties resulting from the initiation and continuation of patent litigation or other proceedings
could have a material adverse effect on our ability to compete in the marketplace.

51

In
addition, our patents and patent applications, and patents and patent applications that we may apply for, own or license in the future,
could face other challenges